Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
Should you buy Microsoft before today’s earnings announcement?
As Microsoft gears up to reveal its quarterly earnings after the market closes, all eyes are on the tech giant,…
US Consumer Sentiment Tops Estimates In January, Hits Highest Level Since July 2021: Friday’s Economic Digest
U.S. consumer confidence in January continues to exceed even the most optimistic expectations among analysts, reaching its highest levels in…